Entrada Therapeutics (TRDA) Other financing activities (2020 - 2026)

Entrada Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 71.43% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $212000.0 (down 70.47% YoY), while the FY2025 annual figure was $462000.0, down 19.51% from the prior year.
• Other financing activities for Q1 2026 stood at $100000.0, up from $84000.0 in the prior quarter.
• The five-year high for Other financing activities was $1.1 million in Q2 2024, with the low at -$1.0 million in Q3 2024.
• The 5-year median for Other financing activities is $100000.0 (2026), against an average of $104352.9.
• Peak annual rise in Other financing activities reached 614.0% in 2023, while the deepest fall reached 520.27% in 2023.
• Entrada Therapeutics' Other financing activities stood at $74000.0 in 2022, then tumbled by 520.27% to -$311000.0 in 2023, then surged by 200.0% to $311000.0 in 2024, then tumbled by 72.99% to $84000.0 in 2025, then advanced by 19.05% to $100000.0 in 2026.
• Business Quant data shows TRDA's Other financing activities at $100000.0 in Q1 2026, $84000.0 in Q4 2025, and $8000.0 in Q3 2025.